Tissue-engineered kidney disease models
Open accessThe DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.
Abstract
Renal disease represents a major health problem that often results in end-stage renal failure necessitating dialysis and eventually transplantation. Historically these diseases have been studied with patient observation and screening, animal models, and two-dimensional cell culture. In this review, we focus on recent advances in tissue engineered kidney disease models that have the capacity to compensate for the limitations of traditional modalities. The cells and materials utilized to develop these models are discussed and tissue engineered models of polycystic kidney disease, drug-induced nephrotoxicity, and the glomerulus are examined in detail. The application of these models has the potential to direct future disease treatments and preclinical drug development.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Effects of substrate stiffness on cell morphology, cytoskeletal structure, and adhesion
Yeung, T., Georges, P. C., Flanagan, L. A., Marg, B., Ortiz, M., Funaki, M., Zahir, N., Ming, W., Weaver, V., & Janmey, P. A. (2005) · Cell Motility and the Cytoskeleton · doi:10.1002/cm.20041 · Cited by 2,325
Concordance of the toxicity of pharmaceuticals in humans and in animals
Olson, H., Betton, G., Robinson, D., Thomas, K., Monro, A., Kolaja, G., Lilly, P., Sanders, J., Sipes, G., Bracken, W., et al. (2000) · Regulatory Toxicology and Pharmacology · doi:10.1006/rtph.2000.1399 · Cited by 2,050 · cited 3×
“However, this method is not very predictive as indicated by the low success rates of drugs that make it to clinical trials [2,108,113].”
BackgroundMethodFrom 3D cell culture to organs-on-chips
Huh, D., Hamilton, G. A., & Ingber, D. E. (2011) · Trends in Cell Biology · doi:10.1016/j.tcb.2011.09.005 · Cited by 1,834
Autosomal dominant polycystic kidney disease
Torres, V. E., Harris, P. C., & Pirson, Y. (2007) · The Lancet · doi:10.1016/s0140-6736(07)60601-1 · Cited by 1,550
Regeneration and experimental orthotopic transplantation of a bioengineered kidney
Song, J. J., Guyette, J. P., Gilpin, S. E., Gonzalez, G., Vacanti, J. P., & Ott, H. C. (2013) · Nature Medicine · doi:10.1038/nm.3154 · Cited by 793 · cited 2×
“2 Decellularized Kidneys—While decellularized kidneys are a relatively new advance, techniques have been developed to decellularize rat [59-61], porcine [61-63], rhesus monkey [64-66], and human [61] kidneys with the benefit being that decellularized organs maintain the complex architecture and native biological signa…”
BackgroundMethodSullivan, D. C., Mirmalek-Sani, S.-H., Deegan, D. B., Baptista, P. M., Aboushwareb, T., Atala, A., & Yoo, J. J. (2012) · Biomaterials · doi:10.1016/j.biomaterials.2012.07.023 · Cited by 363
Activating AMP-activated protein kinase (AMPK) slows renal cystogenesis
Takiar, V., Nishio, S., Seo-Mayer, P., King, J. D., Li, H., Zhang, L., Karihaloo, A., Hallows, K. R., Somlo, S., & Caplan, M. J. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1011498108 · Cited by 345
Charytan, D., & Kuntz, R. E. (2006) · Kidney International · doi:10.1038/sj.ki.5001934 · Cited by 271 · cited 1×
“Finally, DIN is often far worse in patients who are already suffering from acute kidney injury or chronic kidney disease and these patients are rarely modeled in 2D or animal models and are often also left out of clinical trials [126].”
BackgroundOrlando, G., Farney, A. C., Iskandar, S. S., Mirmalek-Sani, S.-H., Sullivan, D. C., Moran, E., AbouShwareb, T., De Coppi, P., Wood, K. J., Stratta, R. J., et al. (2012) · Annals of Surgery · doi:10.1097/sla.0b013e31825a02ab · Cited by 229
Duan, Y., Gotoh, N., Yan, Q., Du, Z., Weinstein, A. M., Wang, T., & Weinbaum, S. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0804954105 · Cited by 185 · cited 1×
“This is particularly significant for the kidney nephron as changes in fluid flow have been linked to kidney cell function and diseases such as PKD [68-71].”
Background
Cited by
Bioprinting of 3D convoluted renal proximal tubules on perfusable chips
Homan, K. A., Kolesky, D. B., Skylar-Scott, M. A., Herrmann, J., Obuobi, H., Moisan, A., & Lewis, J. A. (2016) · Scientific Reports · doi:10.1038/srep34845 · Cited by 699
Engineered In Vitro Disease Models
Benam, K. H., Dauth, S., Hassell, B., Herland, A., Jain, A., Jang, K.-J., Karalis, K., Kim, H. J., MacQueen, L., Mahmoodian, R., et al. (2015) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev-pathol-012414-040418 · Cited by 554
Kidney-on-a-Chip technology for drug-induced nephrotoxicity screening
Wilmer, M. J., Ng, C. P., Lanz, H. L., Vulto, P., Suter-Dick, L., & Masereeuw, R. (2016) · Trends in Biotechnology · doi:10.1016/j.tibtech.2015.11.001 · Cited by 354
Three‑dimensional cell culture: A powerful tool in tumor research and drug discovery (Review)
Lv, D., Hu, Z., Lu, L., Lu, H., & Xu, X. (2017) · Oncology Letters · doi:10.3892/ol.2017.7134 · Cited by 337
Huang, B.-W., & Gao, J.-Q. (2018) · Journal of Controlled Release · doi:10.1016/j.jconrel.2017.12.005 · Cited by 174
Metadata
- Authors
- DesRochers, T. M., Palma, E., & Kaplan, D. L.
- Venue
- Advanced Drug Delivery Reviews
- Publisher
- Elsevier BV
- Published
- 2014-04
- Volume
- 69-70
- Pages
- 67-80
- ISSN
- 0169-409X (ISSN-L)
- OpenAlex
- W2099638616
- Cited by
- 98
- References
- 12
- FWCI
- 1.65
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Tissue-engineered kidney disease models. https://app.cochat.ai/papers/10.1016/j.addr.2013.12.002
- The paper
- DesRochers, T. M., Palma, E., & Kaplan, D. L. (2014). Tissue-engineered kidney disease models. Advanced Drug Delivery Reviews. https://doi.org/10.1016/j.addr.2013.12.002
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.